Scarica l'app Stockscreener
18.44
2.90%
-0.55
Dopo l'orario di chiusura:
18.58
0.14
+0.76%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Precedente Chiudi:
$18.99
Aprire:
$18.94
Volume 24 ore:
791.76K
Relative Volume:
0.75
Capitalizzazione di mercato:
$1.57B
Reddito:
-
Utile/perdita netta:
$-230.32M
Rapporto P/E:
-5.2299
EPS:
-3.5259
Flusso di cassa netto:
$-196.04M
1 W Prestazione:
-3.05%
1M Prestazione:
-5.29%
6M Prestazione:
+17.68%
1 anno Prestazione:
-63.44%
Intervallo 1D:
$18.37
$18.96
Intervallo di 1 settimana:
$18.30
$20.00
Portata 52W:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Nome
Moonlake Immunotherapeutics
Settore
Industria
Telefono
41 41 510 8022
Indirizzo
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
18.44 | 1.69B | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-23 | Aggiornamento | Wolfe Research | Underperform → Outperform |
| 2026-03-19 | Aggiornamento | Rothschild & Co Redburn | Neutral → Buy |
| 2026-01-15 | Downgrade | Goldman | Neutral → Sell |
| 2026-01-09 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-11-03 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | Downgrade | Goldman | Buy → Neutral |
| 2025-09-30 | Downgrade | Citigroup | Buy → Neutral |
| 2025-09-30 | Downgrade | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-09-29 | Downgrade | Jefferies | Buy → Hold |
| 2025-09-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | Downgrade | Stifel | Buy → Hold |
| 2025-07-28 | Iniziato | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-11-05 | Ripresa | Wedbush | Outperform |
| 2024-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-02 | Iniziato | Goldman | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Citigroup | Buy |
| 2023-11-02 | Iniziato | Stifel | Buy |
| 2023-09-14 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Iniziato | Needham | Buy |
| 2023-06-15 | Iniziato | Barclays | Equal Weight |
| 2023-05-01 | Iniziato | Guggenheim | Buy |
| 2023-03-22 | Iniziato | Wedbush | Outperform |
| 2023-03-09 | Iniziato | BTIG Research | Buy |
| 2023-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Iniziato | Bryan Garnier | Buy |
| 2022-11-11 | Iniziato | Jefferies | Buy |
| 2022-08-25 | Iniziato | SVB Leerink | Outperform |
| 2022-07-21 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-07 | Iniziato | Cowen | Outperform |
Mostra tutto
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
MoonLake Immunotherapeutics (MLTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
MoonLake Immunotherapeutics (MLTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MLTX|MoonLake Immunotherapeutics|Price:19.890|Chg%:+0.870 - TradingKey
TradingKey - TradingKey
MoonLake Immunotherapeutics (MLTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MLTX|MoonLake Immunotherapeutics|Price:19.020|Chg%:-0.340 - TradingKey
What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors - Kavout | AI
MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits
MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts - Stocktwits
MoonLake Immunotherapeutics CSO Kristian Reich disposes of $1 million in common shares - Bitget
Form 4 MoonLake Immunotherapeutics For: 21 July By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Moonlake stock buy rating on funding By Investing.com - Investing.com South Africa
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits
H.C. Wainwright reiterates Moonlake stock buy rating on funding - Investing.com
Analyst Maintains Buy on MoonLake, Reiterates $45 Price Target on Strong Financing and Sonelokimab Commercial Potential - TipRanks
MoonLake Immunotherapeutics (NASDAQ: MLTX) CSO entity sells 16,105 shares - Stock Titan
MoonLake Immunotherapeutics CSO Kristian Reich sells 16,105 shares for $322,261.05 - Bitget
Behavioral Patterns of MLTX and Institutional Flows - Stock Traders Daily
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites - Stocktwits
MoonLake Immunotherapeutics (MLTX) Surges 4.6%: Key Levels to WatchETF NAV Deviation - dars.gov.et
MoonLake Immunotherapeutics prices $200M public offering of Class A shares - MSN
Moonlake Therapeutics raises USD 230 million in public offering - Startupticker.ch
Form 144 MoonLake Immunotherapeutics For: 15 July By Investing.com - Investing.com India
MoonLake Immunotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Jerucon plans 150,000-share MLTX sale in Form 144 (Nasdaq: MLTX) - Stock Titan
MoonLake Immunotherapeutics Announces Public Offering of Class A Shares on NASDAQ – 8-K Filing Details - Minichart
MoonLake Immunotherapeutics (NASDAQ: MLTX) raises $30M via option exercise - Stock Titan
Insider Sell: Santos da Silva Jorge Sells 102,225 Shares of Moon - GuruFocus
Insider Sell: Santos da Silva Jorge Sells 102,225 Shares of MoonLake Immunotherapeutics (MLTX) - GuruFocus
[Form 4] MoonLake Immunotherapeutics Insider Trading Activity - Stock Titan
SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears - Yahoo Finance
MoonLake Immunotherapeutics' CFO Sells 39K Shares - The Motley Fool
Insider Sell: Santos da Silva Jorge Sells 47,775 Shares of MoonL - GuruFocus
CEO of MoonLake Immunotherapeutics (NASDAQ: MLTX) sells shares under plan - Stock Titan
Class Action Lawsuit Filed Against MoonLake Immunotherapeutics (M - The National Law Review
MoonLake Reports Positive 52-Week Phase 3 Data for Sonelokimab in Hidradenitis Suppurativa - Dermatology Times
Top biotech stocks to watch in second half of 2026, says Clear Street - Investing.com South Africa
MLTX Maintained by Leerink Partners -- Price Target Raised to $2 - GuruFocus
Leerink raises Moonlake stock price target on HS drug data By Investing.com - Investing.com South Africa
Leerink raises Moonlake stock price target on HS drug data - Investing.com
Form 144 MoonLake Immunotherapeutics For: 30 June By Investing.com - Investing.com South Africa
Moonlake Immunotherapeutics Azioni (MLTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moonlake Immunotherapeutics Azioni (MLTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Reich Kristian | Chief Scientific Officer |
Jul 21 '26 |
Sale |
20.02 |
50,000 |
1,001,000 |
2,714,746 |
| Reich Kristian | Chief Scientific Officer |
Jul 22 '26 |
Sale |
20.00 |
2,448 |
48,960 |
2,712,298 |
| Reich Kristian | Chief Scientific Officer |
Jul 20 '26 |
Sale |
20.09 |
43,700 |
877,933 |
2,764,746 |
| Reich Kristian | Chief Scientific Officer |
Jul 15 '26 |
Sale |
20.01 |
16,105 |
322,261 |
2,808,446 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):